The long-term outlook for essential thrombocythemia

Mayo Clinic Proceedings

Volumn 81, Issue 2, 2006, Pages 157-158

  Campbell, Peter J ^b   Green, Anthony R ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; BUSULFAN; CHLORAMBUCIL; HYDROXYUREA; JANUS KINASE 2; PHOSPHORUS;

DISEASE COURSE; EDITORIAL; GENE MUTATION; HUMAN; LEUKEMOGENESIS; LEUKOCYTE COUNT; MALIGNANT TRANSFORMATION; MYELOID LEUKEMIA; OVERALL SURVIVAL; PROGNOSIS; RISK FACTOR; THROMBOCYTHEMIA; THROMBOSIS;

EID: 32144432164     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.2.157     Document Type: Editorial

References (9)

1. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81:159-166.
2. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304:441-447.
3. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33-45.
4. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132-1136.
5. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100:4272-4290.
6. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-1018.
7. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96:4261-4266.
8. Campbell PJ, Scott LM, Buck G, et al, United Kingdom Myeloproliferative Disorders Study Group, Medical Research Council Adult Leukaemia Working Party, Australasian Leukaemia and Lymphoma Group. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945-1953.
9. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005;131:208-213.